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A B S T R A C T
Osteogenesis imperfecta or brittle bone disease, a heritable disorder of connective tissue, is the most common of the in-
herited disorders primarily affecting bone. There are approximately 400 individuals with OI in Croatia alone. It is esti-
mated that twice that number is present, represented by individuals with mild OI in whom the diagnosis has not been
made. Due to the relatively low number of patients in the general population, treating physicians have limited experience
with this disease, either with children or adults. The basis of this disease in European populations is mostly the result of
defects in the structure or processing of collagen type I, an important protein of the extracellular matrix of many tissues.
Presently, molecular defects in 16 different genes have been discovered to result in at least one type of OI of which 14 are
not COL1 mutation loci. Although fractures occurring with no injury or minor injury are the hallmark of OI, other
non-mineralized tissues can be affected as well and the pathological changes can be present in skin, tendons, eyes, teeth
and blood vessels. Clinical manifestations are very heterogeneous and numerous signs and symptoms such as blue sclera,
deafness, abnormal teeth development, joint hypermobility, increased risk of hernias, capillary fragility, aneurysms etc.
Although there is no cure for this disease, there are specific therapies that can reduce the pain and complications associ-
ated with OI. The purpose of this review is to provide a brief overview of the molecular basis of this disease, describe clini-
cal presentations, as well as to present orthopaedic therapeutic modalities for the patients with OI.
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Classification and Clinical Picture
Osteogenesis imperfecta (OI) or brittle bone disease is
the name for a group of heritable disorders of connective
tissue which are associated with osteoporosis and vari-
able amount of skeletal deformities1,2. It is estimated
that the prevalence of OI is 1 in 15,000–20,000 infants.
Osteogenesis imperfecta is a very complex life-long dis-
ease for which pediatrician and orthopedic surgeon will
play an essential role in developing a plan that optimizes
the quality of life for patients. An extensive literature
has grown up on this subject3–9. Clinical features of OI
vary in severity, frommild to neonatal lethal forms. Bone
fragility in OI is the result of a failure of the osteobleasts
to synthesize adequate amounts of normal skeletal ma-
trix and it is important to notice that increased osteo-
clastic bone resorption in not responsible for the osteo-
penia of OI.
All forms of OI are genetic and severity depends on
the specific gene defect and the quality of perinatal and
postnatal care as well as the underlying genetic defect. In
1978, Sillence, classified OI into four major clinical ty-
pes10. That classification was modified several times but
The International Nomenclature Committee for Consti-
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tutional Disorders of the Skeleton (2010) recommended
that the nosology should abandon the numerical nomen-
clature and group OI Syndrome into 5 major clinical enti-
ties: Non-deforming OI with Blue Sclerae (OI type I),
Perinatally Lethal OI (Type II), Progressively Deforming
OI (Type III), Common Variable OI with Normal Sclerae
(OI type IV) and OI with calcification in inter-osseous
membranes (OI type V). The proposed classification is
based on clinical and radiological features as well as on
inheritance patterns11. While genetic databases such as
OMIM (On-line Mendelian Inheritance in Man) continue
to give numbers as each new gene is discovered, the No-
menclature committee recommended these OMIM enti-
ties be incorporated into the clinical genetic phenotypes.
The most common complications of OI related to mortal-
ity include declining pulmonary function in childhood
and cor pulmonale in adulthood, both of which it is hoped
are prevented by a modern approach to therapy. Basilar
invagination is an uncommon but potentially fatal com-
plication of Osteogenesis imperfecta.
Molecular Basis of Osteogenesis imperfecta
During the last years the molecular concept of OI
changed from the hypothesis of a single gene disorder to
that of a disorder with multiple genetic cause disorder.
For decades researchers were convinced that type I colla-
gen was exclusively responsible for this disease. Pro-
pelled by advancement in molecular genetics it has been
possible to show that OI is result of different mutations
at least of 16 different gene loci. However, in European
populations most of the OI phenotypes are the result of
different mutations affecting the collagen genes COL1A1
and COL1A2 genes. Collagens belonging to a family of
fibrillar proteins that support almost all tissues in the
body, including bone, tendon, skin, cartilage, blood ves-
sels, sclerae, lung, dentin, heart valves, fascia, cornea,
liver, etc. Collagen type I, however, is the most abundant
protein in human body and is coded by two separate
genes COL1A1 and COL1A2 that produce the pro-alpha
1 and pro-alpha 2 chains of type I collagen. Type I colla-
gen mainly participates in building extracellular matrix
of bone, dentine and skin. It is known that mutations in
COL1A1 gene are also responsible for several different
health conditions including OI, Ehlers-Danlos syndrome,
dermatofibrosarcoma protuberans and infantile cortical
hyperostosis (Caffey disease)12.
Autosomal Dominant OI
Heterozygous dominant negative mutations includ-
ing glycine substitution mutations (the most common de-
fect), helical splicing mutations (mainly mutations with-
in donor or acceptor sequences of either gene has been
associated with exon skipping) produce abnormalities in
the sequence of different regions of the type I collagen
gene and result in expression of a mutant protein that
drastically affects the normal triple-helix configuration.
On the other hand, quantitative mutations represented
by null allele mutations may result in a 50% reduction of
total collagen mRNA, creating a mild clinical phenotype
of OI. Earlier we have described that a substitution at
the +1 position of donor splice site causing intron reten-
tion eventually results in an out-of-frame mRNA con-
taining a premature termination codon3,9.
The mode of inheritance in OI is almost always domi-
nant and there is a known incidence of new mutations.
The risk of an affected individual passing the mutated
gene to the child is 50% while the empirical recurrence
risk that clinically healthy parents are having a second
child with OI is between 5–7 %13 as a result of parent go-
nadal mosaicism or recessive inheritance. Dominant in-
heritance of OI usually results from mutations in COL-
1A1 or COL1A2 genes (Types I–IV OI) or with a unique
defect in the gene encoding osteoblast marker-inter-
feron-induced transmembrane protein 5 (IFITM5) other-
wise termed bone-restricted ifitm-like protein (Bril) (Type
V OI)14.
Autosomal Recessive OI
Recent findings showed that mutations on CRTAP,
LEPRE1, PPIB, are responsible for recessive OMIM
types VII, VIII and IX respectively. Both Progressively
Deforming OI and Perinatally Lethal OI may result from
mutations in these genes. On the other hand defects in
genes SERPINH1 and FKBP10, cause autosomal reces-
sive OMIM types X and XI OI correspondingly11, 12. Most
likely, recessive OI, is caused by defects in genes whose
product interacts with type I collagen for either modifica-
tion or /and folding. CRTAP, LEPRE1 and PPIB genes
encode components of the prolyl-3-hydroxylase complex,
which can modify Pro986 in the a1 chains of type I colla-
gen while SERPINH1 and FKBP10 encode chaperones,
which may be important for proper folding of procollagen
15. Additional recessive OI (Type VI OI) is related with
SERPINF1 gene that encodes pigment epithelium-de-
rived factor (PEDF) and apparently do not have direct
link to collagen, changed standard paradigm that colla-
gen biosynthesis is primarily responsible for OI16,17. Fur-
thermore, it is believed that PEDF plays several impor-
tant roles including inhibition of angiogenesis as well as
endochondral bone formation. Therefore it is possible
that loss of PEDF function with inactivating mutation in
SERPINF1 may result in decreasing numbers of osteo-
blasts and in increasing activity of osteoclasts which can
initiate a decrease bone formation or enhance bone re-
sorption. Also, we should not exclude the possibility that
the PEDF has a direct role in collagen biosynthesis15.
Progressively Deforming autosomal recessive Osteogene-
sis imperfecta may also result from mutations in several
other genes. It is believed that the protein products of
these genes interact with collagen post-translationally
for folding, modification, or crosslinking, resulting in a
collagen-related paradigm for OI18. Furthermore, muta-
tion on BMP1 (bone morphogenetic protein 1) gene was
associated with OMIM Type XII OI (18). Finally, Moder-
ately severe OI type IV or Progressively Deforming OI
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may result from mutations in SP7 gene (Zinc-finger
transcription factor defect), TMEM38B gene (Cation
Channel defect) or WNT1 gene (WNT signaling pathway
defect)18.
One of the best resources of gene variants of COL1A1,
COL1A2, BMP1, CRTAP, FKBP10, LEPRE1, PLOD2,
PPIB, SERPINF1, SERPINH1 and SP7 that cause OI is
available at: www.le.ac.uk/genetics/collagen
Osteogenesis Imperfecta – Diagnosis and
testing
Dermal biopsies were the standard for OI diagnosis
for many years. A diagnosis of OI is usualy confirmed by
biochemical analysis of the Collagen Type I polypeptides
produced by cultured skin fibroblasts from the patients
with OI associated mutations in COL1A1 and COL1A2
genes. Basically, two findings are possible, either a reduc-
tion of the amount or polypeptide produced or changes in
electrophoretic mobility of on of the chains of type I colla-
gen. Since biochemical testing requires work with fibro-
blast cultures it usually takes several months to investi-
gate. Furthermore mutations which result in only a
quantitative reduction in type I collagen polypeptides are
not able to be simply characterized. However, genetic
testing (particularly genomic DNA sequencing) is much
more efficient and requires less time. Genetic diagnostic
of OI after chronic villus biopsy (between 14–20 weeks) is
also possible.
General and Orthopaedic Management of
Patients with Osteogenesis Imperfecta
The main orthopaedic feature of all types of Osteoge-
nesis imperfecta is increased fragility of bones. Parents of
newly born child are under additional pressure due to
the fact that routine child nursing could lead to their
newborn long bone fracture. Those fractures and resid-
ual deformities of lower extremities are crucial obstacles
for locomotion and subsequent neuromuscular develop-
ment of the growing child. A significant amount of knowl-
edge on medical and surgical treatment of OI has accu-
mulated in the medical literature, in recent years. It is
purpose of this article to present current status of ge-
netic background as well as advances in medical and sur-
gical treatment of OI that is available in Croatia. It is es-
sential for the family practitioner and general physician
to have sound knowledge on paradigmatic rare diseases
and OI is a perfect example.
The secondary consequences of OI are hearing im-
pairment, dental abnormalities, symptoms and signs
neurological features due to macrocephaly, hydrocepha-
lus, syringomyelia and basilar invagination (an infolding
of the skull base that leads to brainstem distortion). It is
obvious that multi-systemic disease requires multi spe-
cialist management approach. A fully aware physician
should pay attention that in child with OI there are
many potential health issues which, on the first sight,
could be hidden »under the surface«. Additionally, it is
not only the child with OI who is sick, it is whole family.
OI is a kind of multi-systemic disease that affects the
whole normal routine life of the family.
A Team approach is a cornerstone of good medical
practice in the management of OI. Treatment should be
focused to the main goal i.e. to restore function to the ex-
tremities. To obtain this goal we can use careful and indi-
vidualized rehabilitation and physical therapy to pro-
mote increased strength and mobility. This should be
provided in specialized clinical centres for OI. Second, we
could use bisphosphonates as antiresorptive pharmaco-
logical therapy. All types of OI result in fragile bones due
to low quality of bone material; bone mass is diminished
because bone turnover is higher resulting in less tra-
becular bone formed than resorbed. In addition, there is
poor cortical modeling due to insufficient osteoblast per-
formance. Also, bone geometry is distorted. It is well doc-
umented in the medical literature that bisphosphonates
are useful to improve bone strength, motor function, de-
crease pain and improve vertebral geometry. In the most
severe cases of OI cyclic intravenous administration of
bisphosphonates could be introduced even before walk-
ing age. Generally, bisphosphonate treatment is indi-
cated when the patient has more than two fractures of
long bone annually and compressive fractures of verte-
bral bodies. However, firstly we should assess the sever-
ity of clinical manifestations in each OI patient. In Cro-
atia, medical management with intravenous (pamidronate)
or oral (alendronate) administration is possible in most
major paediatric departments throughout the country.
Orthopaedic i.e. surgical treatment of fractures and
deformities of lower extremity long bones is mainstay of
lifelong management. Corrective surgery is crucial for
ambulation due to the fact that bowed long bone soon
will be fractured on the apex of bow. In the last ten years
telescoping intra-medullary rods have been subject of
substantial improvement19. The first version of telescop-
ing rod i.e. Dubow-Bailey has improved version known
now as Sheffield rod. The third generation of telescoping
rods is Fassier-Duval (F-D) rod which has the advantage
of percutaneous insertion with minimal soft tissue trau-
ma20. Specific construction of the F-D rod enables avoid-
ing of knee and/or ankle joint arthrotomy. Telescoping
rods are intra-medullary implants which are keeping
long bone straight and preventing fractures21. One should
consider intra-medullary rods as internal splints. On
negative side, those rods could migrate proximally and
distally22,23. Some surgeons prefer to apply interlocking
of distal anchorage of F-D rod as it is shown on example
of tibial rodding (Figure 1).
Occasionally, one can use non-telescoping rods e.g.
Kirschner wires or flexible titanium nails (Nancy) (Fig-
ure 2). This procedure could be utilized as single or double
nail technique. Any type of surgery should be followed by
early rehabilitation. Application of Fassier-Duval (F-D)
rod is not a routine orthopaedic procedure and it is not
advisable to perform it outside of specialized centre for
OI patients. Currently, in Croatia, the Orthopaedic de-
partment of University of Zagreb is an institution which
has all prerequisites for routine F-D telescoping rodding
surgery24. Brief overview of our hospital data has shown
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that, up to now, one hundred and ten surgical procedures
were performed in 28 patients who suffered from Osteo-
genesis imperfecta. Eleven patients (25 long-bone seg-
ments) were treated with telescoping intramedullary nail.
In seven patients (18 segments) Fassier-Duval telescop-
ing intramedullary nail was inserted. With an aim to en-
able patients to walk, in two of them both femurs and
both tibias were corrected and protected from further
fractures with third generation I-M nails i.e. Fassier-
-Duval (Figure 3).
Stem Cells and Gene Therapy in
Osteogenesis Imperfecta
Since bisphosphonates cannot correct the primary
cause of OI, and their long-term use and effectiveness are
still uncertain, new treatment options are being devel-
oped by scientists and clinicians. Stem cells are self-re-
newing, multipotential cells capable of differentiating into
multiple different cell types. These properties provide
many advantages for the development of novel therapeu-
tic strategies, and stem cells continue to be of unprece-
dented public, scientific and clinical interest. Mesenchy-
mal stem cells (MSCs) have been particularly interesting
for application in the treatment of musculoskeletal pa-
thology since they are able to differentiate along specific
tissue lineages (osteogenic, adipogenic, chondrogenic etc.),
and possess trophic and immunomodulatory capabili-
ties25. Rationale for their use in the treatment of OI lays
in the assumption that allogeneic transplantation of MSCs
into the OI patient provides sufficient amounts of healt-
hy osteoblasts, capable of producing normal collagen,
and therefore normal bone. After first success on murine
model, first clinical trial took place in late 90s26,27. Child-
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Fig. 1. (A) Preoperative radiograph of the patient with OI. (B) Postoperative roentgenogram of the same patient after bilateral tibial cor-
rective osteotomies with K-wires. (C) Reappearance of angular deformation two years after the surgery. (D) AP radiograph of the second
corrective osteotomy with Fassier-Duval rod. (E) LL radiograph of the second corrective osteotomy with Fassier-Duval rod.
Fig. 2. Postoperative radiographs of the patient after corrective
osteotomies of ipsilateral tibia (K-wire) and femur (Fassier-Duval
rod).
Fig. 3. Roentgenograms of the patient three years after the correc-
tive procedures with Fassier-Duval’s intramedullary nailing.
ren with severe type III OI were treated with transplan-
tation of allogeneic bone marrow, which resulted in de-
creased number of fractures and better bone mineralization.
Approximately portion of donor osteoblasts within the
whole population was 1–2%. With the hypothesis that the
mesenchymal component is responsible for observed ef-
fects, another study on the same patient followed. This
time the patients received isolated and expanded bone
marrow-derived MSCs28. Similar to the first study, donor
cells were detected in various tissues, including osteo-
blasts and skin fibroblasts producing improvement of
clinical status of the patients. Unfortunately, in both of
these studies, the therapeutic effect was short-termed,
and the portion of healthy donor osteoblasts was rela-
tively minor.
Gene therapy is another feasible option, relying on
the observed fact the analysis of individuals who are so-
matic mosaics for an OI mutation but do not have evi-
dence of active disease29. Those studies suggest that the
deleterious effect of OI cells can be compensated for by
the presence of normal cells. Thus, if it were possible to
introduce normal cells into an individual with OI, the se-
verity of bone disease would be reduced. To achieve these
goals different strategies were employed. This process in-
volves two steps: the inhibition of the output from the
mutant collagen allele and an insertion of replacement
collagen gene for the inactivated mutant gene. Once cor-
rected, the engineered cells should be able to engraft
bone, proliferate, and participate in new bone formation.
The successful gene therapy heavily relies on vectors
used to deliver cDNA to target cells. Viral vectors such as
adenovirus, adeno-associated virus, lentivirus or retro-
virus are very efficient but carry risk of immunological
response or insertional mutagenesis30. On the other hand,
non-viral methods rely on importing naked DNA in to
the cell by changing its physical and chemical properties,
such as lipids, polymers and electroporation. This ap-
proach is safe, but is substantially less effective in com-
parison to viral vectors.
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OSTEOGENESIS IMPERFECTA – VI[E-SUSTAVNA, DO@IVOTNA BOLESTI I NJEN UTJECAJ NA
OBITELJ
S A @ E T A K
Osteogenesis imperfecta (OI) ili bolest krhkih kostiju naj~e{}a je nasljedna bolest koja primarno poga|a ko{tano
tkivo. Prema dostupnim podacima u Hrvatskoj od OI boluje oko 400 pojedinaca, a procijenjuje se da jo{ dvostruko toliko
ljudi boluje od bla`eg oblika bolesti, te stoga niti dijagnoza nije postavljena. Kako se radi o relativnom malom broju
oboljelih, ve}ina lije~nika ima ograni~eno iskustvo u lije~enju ovih bolesnika, bilo da se radi o djeci ili o odraslima. U
podlozi OI nalazi se abnormalna sinteza kolagena, koji je glavni protein izvanstani~nog matriksa mnogih tkiva. Iako
klini~kom slikom dominiraju prijelomi, zahva}ena su i nemineralizirana tkiva te se promijene o~ituju na a ko`i, teti-
vama, bjeloo~nicama, zubima i krvnim `ilama. Klini~ka slika je vrlo heterogena te se mogu pojaviti znakovi i simptomi
kao {to su plavkasta obojenost bjeloo~nica, gluho}a, poreme}aj u razvoju zuba, pove}an opseg pokreta u zglobovima
(hiperlaksitet) i elasticitet ko`e, sklonost hernijama (kilama), krhkost kapilara, aneurizme, mlohavost sr~anih zalis-
taka i dr. Iako ne postoji mogu}nost izlije~enja ovih bolesnika, na raspolaganju nam stoji ~itav niz specifi~nih tera-
peutskih procedura koje mogu smanjiti bol i komplikacije povezane s osnovnom bole{}u, te zna~ajno pove}ati kvalitetu
`ivota bolesnika s OI. Cilj ovog preglednog ~lanka je prikazati molekularnu osnovu bolesti, opisati klini~ku sliku te
prikazati najosnovnije modalitete ortopedskog lije~enja pacijenata s OI.
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